Concert: Phase III THRIVE-AA2 trial of CTP 543 in alopecia areata presented at the American Academy of Dermatology's (AAD) 2023 Annual Meeting.- Concert Pharma

Concert Pharmaceuticals announced the presentation of data from its Phase III clinical trial, THRIVE-AA2 evaluating the oral investigational medicine CTP 543 (deuruxolitinib) in adult patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete scalp hair loss.